SEOUL-SEMICONDUCTOR
24.5.2017 09:09:07 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) — On April 28, 2017, Seoul Semiconductor Europe GmbH (“Seoul”) filed a patent infringement claim in Germany at the District Court of Düsseldorf against Mouser Electronic Inc. (“Mouser), a global electronic components distributor, which it accused of selling Everlight LED products.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170524005266/en/
In its complaint, Seoul asserted that Everlight’s Mid-Power LED products are infringing Seoul’s patent rights. Seoul has sought a permanent injunction, damages, and recall and destruction of the allegedly infringing products.
The asserted patent serves to improve the light extraction performance of LED devices by enhancing internal-reflection efficiency, which has been widely used in mid-power and high-power LEDs.
This patent litigation is the second patent infringement litigation by Seoul or its affiliate affecting Everlight’s LED products. In March 2017, Seoul Semiconductor Co., Ltd. filed a patent infringement claim in Germany, accusing high-power LED products manufactured by Everlight as well as other LED manufacturers. These patent litigations underscore Seoul’s commitment to protecting its intellectual property rights against infringement, including products consisting of mid-power LEDs and high-power LEDs.
In addition to Seoul’s patent infringement actions, Everlight has been implicated in other patent infringement lawsuits as described below. Nam Ki-bum, Vice President of the Research Center at Seoul, said, “Several LED companies have grown rapidly in a short period of time despite a lack of valuable patent portfolios, which is like building a castle on quicksand. There is no underlying foundation for the company’s products. Seoul, however, has been investing 10% of its revenue in research and development for many years to develop innovative technology and strengthen our patent portfolio. To support a fair market that respects intellectual property rights, Seoul will continuously monitor and take action against alleged infringers in any countries where infringement occurs.”
* Reference [source: various media news articles]
| Plaintiff | Defendant | Business Relation | Patented Technology | Courts | State | Link | ||||||
| Nichia | WOFI Leuchten | Everlight subsidiary | phosphor | Düsseldorf District Court, Germany | Nichia won the suit in the court of first instance and the court ruled for an injunction |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | REGO-Lighting | Used a white LED tube light product by Everlight subsidiary Zenar | phosphor | Düsseldorf District Court, Germany | On Dec. 5, 2016, the appeals court confirmed patent infringement and ruled in favor of Nichia. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Everlight | Everlight | phosphor | Düsseldorf District Court, Germany | On Oct. 24, 2016, the court granted a preliminary injunction. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Tachibana Eletech and E&E Japan | Distributor of blue LEDs manufactured by Everlight in Japan | LED chip | Tokyo District Court, Japan | On Oct. 14, 2016, the court issued an oder ruled for an infringement in favor of Nichia. |
http://www.nichia.co.jp/en/about_nichia/2016 |
||||||
| Nichia | Mouser | Distributor of Everlight products | phosphor | Düsseldorf District Court, Germany | On Oct. 7, 2016, the court granted a preliminary injunction. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Everlight | Everlight | LED Package | The U.S. District Court for the Eastern District of Texas | The Federal Circuit affirmed an infringement of Nichia’s patents. |
http://www.nichia.co.jp/en/about_nichia/20
http://www.ledinside.com/news/2017/5/nic |
||||||
| Nichia | EBV Elektronik GmbH & Co. KG and EBV Management GmbH (both “EBV“) | Distributor of Everlight products | phosphor | Düsseldorf District Court, Germany | Still in progress |
http://www.nichia.co.jp/en/about_nichia http://www.ledinside.com/press/2017/3/nichia _files_patent_infringement_lawsuit_against_ |
||||||
| Nichia | Everlight Electronics (China) and Beijing Ducheng Yiguang Electronic Devices Selling Center | Everlight subsidiary | phosphor | Beijing Intellectual Property Court, China | Still in progress |
http://www.nichia.co.jp/en/about_nichia |
||||||
| Seoul Semiconductor | Mouser | Distributor of Everlight products | High Power LED | Düsseldorf District Court, Germany | Still in progress | |||||||
| Seoul Semiconductor | Mouser | Distributor of Everlight products | Mid Power LED | Düsseldorf District Court, Germany | On April 28, 2017, Seoul filed the lawsuit. | |||||||
About Seoul Semiconductor:
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fifth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as Wicop – a simpler structured Package-Free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; Acrich, the world's leading direct AC LED; Acrich MJT multi-junction technology; a proprietary family of high-voltage LEDs; NanoDriver Series – World’s Smallest 24W DC LED Drivers and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs.
For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com
# Trademarks: Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005266/en/
Contact:
Asia
Seoul Semiconductor Co., Ltd
Jake Jung, +82 070.4391.8270
Email:
pr@seoulsemicon.com
or
Europe
Seoul
Semiconductor Europe GmbH
Ariane Heim, +49 (0)89 450 3690-0
Email:
press.eu@seoulsemicon.com
or
North
America
Seoul Semiconductor Inc.
David Cox, +1 (919) 410-9856
Email:
David.cox@seoulsemicon.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom